Tickers

1. Composite Trajectory Verdict

The income statement and cash flow statement carry the most weight for this pre-profitability biopharma transitioning to commercial stage, as they reveal the pace of loss expansion and cash consumption relative to early revenue ramp.

Composite Trajectory: Mixed

Revenue is growing with the launch of KOMZIFTI ($14.9 million in H1 2026 vs $0 in H1 2025) and ongoing Kyowa collaboration payments, but net losses are widening significantly (FY 2025: -$278.7M vs FY 2024: -$174.0M; H1 2026: -$141.7M vs H1 2025: -$123.6M). Operating cash burn is accelerating (FY 2025: -$64.1M vs FY 2024: +$134.3M; H1 2026: -$148.4M vs H1 2025: -$100.7M). The balance sheet shows a large but declining cash position ($519.0M at Jun 2026 vs $667.2M at Dec 2025) and sharply reduced equity ($48.4M vs $174.1M). The improving dimension is top-line revenue initiation; the deteriorating dimensions are profitability, cash generation, and equity erosion.

2. Red Flags

• Operating cash flow swung from +$134.3 million in FY 2024 to -$64.1 million in FY 2025 to -$148.4 million in H1 2026, indicating accelerating cash consumption (10-K FY2025, Consolidated Statements of Cash Flows; 10-Q Q2 2026, Condensed Statements of Cash Flows).
• Net loss widened 60% year-over-year on an annual basis ($174.0M to $278.7M) and 15% on a six-month basis ($123.6M to $141.7M) (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, Condensed Statements of Operations).
• Stockholders' equity fell 72% from $413.6 million at Dec 2024 to $48.4 million at Jun 2026, driven by accumulated deficit growth to $1.316 billion (10-K FY2025, Consolidated Balance Sheets; 10-Q Q2 2026, Condensed Balance Sheets).
• Collaboration revenue is declining as deferred revenue from the Kyowa agreement is recognized ($65.4M FY2025 vs $53.9M FY2024; $24.3M H1 2026 vs $29.4M H1 2025) (10-K FY2025, Consolidated Statements of Operations; 10-Q Q2 2026, Condensed Statements of Operations).
• Product revenue remains minimal relative to operating expenses ($14.9M H1 2026 vs $191.0M total operating expenses) (10-Q Q2 2026, Condensed Statements of Operations).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: Net losses are widening across all comparable periods. FY 2025 net loss of $278.7 million represents a 60% increase over FY 2024's $174.0 million (10-K FY2025, Consolidated Statements of Operations). For the six months ended June 30, 2026, net loss of $141.7 million is 15% larger than the $123.6 million loss in the same period 2025 (10-Q Q2 2026, Condensed Statements of Operations). Total revenue grew to $67.5M in FY 2025 from $53.9M in FY 2024 and to $39.1M in H1 2026 from $29.4M in H1 2025, but operating expenses grew faster: R&D rose 48% annually and 7% semi-annually; SG&A rose 56% annually and 32% semi-annually (10-K FY2025; 10-Q Q2 2026). Loss from operations widened from $193.2M to $303.6M annually and from $137.4M to $151.8M semi-annually.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment: Operating cash flow has shifted from positive to negative and the burn rate is accelerating. FY 2024 generated $134.3 million from operations, but FY 2025 used $64.1 million, a $198.4 million swing (10-K FY2025, Consolidated Statements of Cash Flows). In H1 2026, operating cash outflow was $148.4 million versus $100.7 million in H1 2025, a 47% increase in cash used (10-Q Q2 2026, Condensed Statements of Cash Flows). The increase in cash used was driven by higher net losses and adverse changes in operating assets and liabilities, partially offset by non-cash share-based compensation. Investing activities provided $68.0 million in H1 2026 (vs -$42.5M in H1 2025) due to lower short-term investment purchases, but this reflects portfolio management rather than operating improvement. Financing activities contributed minimally ($1.6M in H1 2026 from equity plans).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Cash, cash equivalents, and short-term investments declined from $727.4M at Dec 2024 (derived: $224.5M cash + $502.9M investments) to $667.2M at Dec 2025 to $519.0M at Jun 2026 (10-K FY2025, Consolidated Balance Sheets; 10-Q Q2 2026, Condensed Balance Sheets). Contract liabilities (deferred Kyowa revenue) remain large at $454.1M (Jun 2026) down from $473.9M (Dec 2025) but up from $278.2M (Dec 2024) (10-K FY2025; 10-Q Q2 2026, Note 7). Long-term debt is stable at $10M drawn. Stockholders' equity fell sharply from $413.6M (Dec 2024) to $174.1M (Dec 2025) to $48.4M (Jun 2026) as accumulated deficit grew to $1.316B (10-K FY2025; 10-Q Q2 2026). The company states current cash plus anticipated Kyowa payments funds operations into Q4 2027 (10-Q Q2 2026, Liquidity Overview).

6. Data Gaps

• No full-year 2026 results available (only H1 2026 10-Q filed).
• Quarterly product revenue trend limited to two quarters (Q4 2025 partial, Q1 2026, Q2 2026) since launch in November 2025.
• No breakdown of cost of product sales beyond aggregate figures ($57K FY2025, $505K H1 2026).
• No disclosure of inventory turnover or accounts receivable aging for product sales.
• Kyowa milestone payment timing and amounts beyond "anticipated $180.0 million" not quantified by period.
• No segment reporting beyond single segment; no geographic breakdown of collaboration revenue recognition.